This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by HARBISON, M. D. Articles by GERTNER, J. M. Search for Related Content PubMed PubMed Citation Articles by HARBISON, M. D. Articles by GERTNER, J. M.

Permissive Action of Growth Hormone on the Renal Response to Dietary Phosphorus Deprivation^*

Department of Pediatrics, Cornell University Medical College New York, New York 10021

Address requests for reprints to: Madeleine D. Harbison, M.D., Department of Pediatrics, Room N-236, New York Hospital-Cornell Medical Center, 525 East 68th Street, New York, New York 10021.

Animal studies have shown that GH is necessary for the increased renal production of calcitriol during dietary phosphorus deprivation (PD). These studies suggest that this adaptive change in vitamin D metabolism is mediated through insulin-like growth factor-I (IGF-I) and/or insulin.

We subjected 16 GH-deficient children to 96 h of severe dietary PD twice, first before and again during recombinant GH replacement. Half of the children received low dose and half received high dose replacement with recombinant GH. We measured renal tubular reabsorption maximum for phosphate corrected for glomerular filtration rate (TmP/GFR), PTH, IGF-I, calcidiol, and calcitriol pre- and postdietary PD, both off and on GH. We also assessed insulin secretion during an oral glucose load (OGTT) off and on GH.

Basal PTH, calcidiol, calcitriol, and fasting blood sugar were unaffected by GH therapy. PD did not affect PTH or calcidiol either off or on GH. Basal TmP/GFR rose on GH therapy (4.8 ± 0.2 to 6.3 ± 0.4 mg/dL) and with PD (4.8 ± 0.2 to 5.7 ± 0.2 mg/dL off and 6.3 ± 0.4 to 7.8 ± 0.3 mg/dL on GH). The increments due to PD and GH therapy were additive. The increments on GH were independent of the GH dose. Before GH replacement, calcitriol did not rise during PD (22.3 ± 2.1 to 23.3 ±1.9 pg/mL), but during GH therapy, PD caused a significant rise in calcitriol (23.8 ± 2.5 to 33.3 ± 2.4 pg/mL; P < 0.0001). The increment in calcitriol during PD was significantly greater in the high dose than it was in the low dose group (11.7 ± 1.5 vs. 7.2 ± 1.6 pg/mL; P < 0.05). GH therapy caused a rise in the IGF-I level that was significantly greater in the high dose (0.26 ± 0.03 to 3.15 ± 0.56 U/mL) than in the low dose (0.27 ± 0.02 to 0.68 ± 0.13 U/mL) group. Insulin in response to OGTT was significantly greater after GH therapy (4155 ± 600 µU/mL·min off GH; 6504 ± 1153 µU/mL·min on GH), although there was no difference between the low and high dose groups. Regression analysis demonstrated a correlation between the change in calcitriol during PD and the IGF-I level (r = 0.83). There was no correlation between insulin levels and the change in calcitriol or between IGF-I or insulin levels and the increment in TmP/GFR during GH therapy.

We conclude that 1) GH exerts an effect on the kidney to cause phosphorus conservation, which may be a direct effect; 2) phosphorus conservation in response to PD is independent of GH in humans; 3) increased calcitriol generation in response to PD is dependent upon GH; 4) the increment in calcitriol during PD correlates significantly with IGF-I levels, but not with insulin, suggesting that it may be an IGF-I-mediated effect of GH.

^* This work was supported by NIH Grant RR-6020 (to the Pediatric Clinical Research Center) and NCI Grant CA-29502 (to the Core Nutritional Research Unit).

Received April 14, 1989.

This article has been cited by other articles:

				H. D. White, A. M. Ahmad, B. H. Durham, S. Chandran, A. Patwala, W. D. Fraser, and J. P. Vora Effect of Active Acromegaly and Its Treatment on Parathyroid Circadian Rhythmicity and Parathyroid Target-Organ Sensitivity J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 913 - 919. [Abstract] [Full Text] [PDF]

				A. M. Ahmad, J. Thomas, A. Clewes, M. T. Hopkins, R. Guzder, H. Ibrahim, B. H. Durham, J. P. Vora, and W. D. Fraser Effects of Growth Hormone Replacement on Parathyroid Hormone Sensitivity and Bone Mineral Metabolism J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2860 - 2868. [Abstract] [Full Text] [PDF]

				N. S. Glaser, A. C. Shirali, D. M. Styne, and K. L. Jones Acid-base Homeostasis in Children With Growth Hormone Deficiency Pediatrics, December 1, 1998; 102(6): 1407 - 1414. [Abstract] [Full Text] [PDF]

				A. M. Boot, M. A. M. J. Engels, G. J. M. Boerma, E. P. Krenning, and S. M. P. F. de Muinck Keizer-Schrama Changes in Bone Mineral Density, Body Composition, and Lipid Metabolism during Growth Hormone (GH) Treatment in Children with GH Deficiency J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2423 - 2428. [Abstract] [Full Text] [PDF]